Europe Epigenetics Diagnostic Market Research Report: Forecast (2025-2030)

Market Definition

Epigenetic diagnostics is the process of examining the effect of environmental factors, such as diet, stress, physical activity, pollution, etc., on the genes of a human body that change their functioning.

Market Insights & Analysis: Europe Epigenetics Diagnostic Market (2025-30):

The Europe Epigenetics Diagnostic Market size was valued at around USD 5.4 billion in 2024 and is projected to reach USD 13 billion by 2030. Along with this, the market is estimated to grow at a CAGR of around 15.8% during the forecast period, i.e., 2025-30. The main reasons behind this growth are the growing demand for personalized medicines, early detection of harmful chronic diseases, reduced treatment costs, enhanced treatment efficiency, and continuous investments in research and development. This is because epigenetic diagnostics helps the healthcare providers in accurately knowing about the infecting cell and give a targeted treatment to the patient which helps in reducing the cost and precisely treating the disease. Such investments also align with regional trends of rising chronic diseases, aging populations, and increasing healthcare awareness.

*Boost strategic growth with in-depth market analysis - Get a free sample preview today!

Moreover, the growth of the market is further fueled by initiatives launched by the European governments. The European Commission launched the Horizon Europe Program in 2021 and it will run till 2027. This program aims to support research and innovations in Europe through funding to improve personalized medicine and healthcare diagnostics, that often use epigenetics in their operations. Additionally, countries such as the UK, France, and Germany are also integrating personalized medicines in their general patient care system, which is achieved through epigenetics diagnostics. This is done by governmental organizations such as the NHS in the UK. Therefore, continuous government support also plays a major role in driving market growth.

Furthermore, the market is further boosted by the aging population in Europe, major of whom are affected by multiple chronic diseases such as diabetes, heart & immune system-related diseases, etc. As per the European Union, about 21.6% of the region’s population is age 65 and above. This further increases the demand for epigenetics diagnostics as they help in knowing the major diseases in their early stages and treating them before they become uncontrollable. Therefore, the market has experienced significant growth in the past years due to the treatment and cost efficiency offered by it, and this trend is expected to continue in the forecast period amid the increasing older population and continuous government support.

Europe Epigenetics Diagnostic Market Driver:

Increasing Cases of Chronic Diseases Driving Market Growth – The number of cases of diseases such as cancer, heart-related diseases, nerves-related diseases, etc., are continuously increasing in this region. As per the WHO, around 20% of the deaths in Europe are caused by cancer. Also, around 32.5% of the deaths were caused by heart-related diseases in 2021. This creates a high need for detecting such problems in their earlier stages and providing the patient with personalized treatment and value-based care. This is achieved through the epigenetics diagnostic which examines the working behavior of cells and helps the healthcare provider observe the progression of treatment. This results in the increased demand for such services in Europe.

Therefore, the increasing number of chronic diseases has increased the demand for epigenetic diagnostics for early detection and personalized medication, and this trend is expected to continue in the forecast period as well

Europe Epigenetics Diagnostic Market Opportunity:

Advancements in Epigenetics Research to Offer Lucrative Growth Opportunity – Various organizations are highly investing in the research and development of epigenetics diagnostics services to expand their usage in the detection of various new diseases. In recent years, DNA methylation’s role has been discovered in various diseases related to the heart and immune system. These include rheumatoid arthritis, multiple sclerosis, atherosclerosis, and others. Moreover, the use of this diagnostic is also discovered in diseases that are not even directly related to epigenetics such as Alzheimer’s disease. Therefore, the high focus on expanding the usage of these services in the detection of multiple diseases will increase their demand in the coming years, thus providing a good growth opportunity for the growth of the market.

Europe Epigenetics Diagnostic Market Challenge:

High Costs to Hinder the Market Growth – The cost of getting the diagnostic of epigenetics is very high, especially when advanced techniques such as next-generation sequencing are used. The approximate cost of NGS is around USD1,000, which makes it difficult for people to afford it, mainly in middle and lower-income countries such as Bulgaria, Ukraine, Romania, and others. This prevents people from investing in epigenetic diagnostics and choosing some alternate methods, such as genetic diagnostics, proteomics, and other blood tests. This results in the decreased adoption of these services.

Moreover, in various countries, epigenetic diagnostics are not covered by insurance companies, so the patients have to pay out of their pocket, which further decreases the adoption of such services. Therefore, the high cost included in this diagnostic is the main reason behind its lower adoption, thus presenting a challenge to the growth of the market.

Europe Epigenetics Diagnostic Market Trend:

Use of AI & ML Gaining Traction – The use of AI and ML in epigenetic diagnostic services has gained popularity in recent years. This is because AI analyzes vast data such as alterations in DNA methylation and histone modifications, to give valuable insights, and ML makes precise predictions based on the given data, that helps in providing precision medicines. This also helps in capturing the minute markers of any disease that are very difficult in manual analysis, which makes it easy to treat such problems in the early stages. As a result, various players in this market have a high focus on AI & ML-based operations. For instance, in 2022, Agilent integrated ACIES, an AI & ML-based software into its mass spectrometry and gas chromatography to increase the efficiency and accuracy in its labs.

Therefore, advanced operations offered by AI & ML have increased their usage in epigenetics diagnostics, and this trend is expected to remain in the coming years as well.

 Europe Epigenetics Diagnostic Market (2025-30): Segmentation Analysis

 The Europe Epigenetics Diagnostic Market study of MarkNtel Advisors evaluates & highlights the major trends and influencing factors in each segment. It includes predictions for the period 2025–30 at the regional level. Based on the analysis, the market has been further classified as:

Based on Method:

• DNA Methylation
• Histone Modifications
• Others

Based on the method used for epigenetics diagnosis, DNA methylation leads the market with a share of around 60%. In this method, various tests such as bisulfite sequencing, NGS, etc., are done to study the DNA methylation, i.e., knowing the DNA where a methyl group (CH₃) is present and causing problems such as cancer. DNA methylation is tested because it is easy to know about the disease as it provides exact information regarding the location of methyl groups, which makes it easier for doctors, even in its starting stages. Moreover, as this method is been around for longer, it is highly available in multiple regions, and that too at low costs, thus attracting more consumers. Therefore, due to its high accuracy & link with the disease, this method has been most widely used in the past years, and this dominance is expected to continue in the future as well.

Based on Product & Service:

• Kits & Reagents
  • Antibodies
  • Chip-Sequencing Kits & Reagents
  • Bisulfite Conversion Kits & Reagents
  • Whole-Genome Amplification Kits & Reagents
  • 5-HMC & 5-MC Analysis Kits & Reagents
  • Histones
  • Others
• Enzymes
  • DNA-Modifying Enzymes
  • Protein-Modifying Enzymes
  • Others
• Instruments & Accessories
• Software
• Services

Based on the type of product and service, kits & reagents dominate the market with a share of around 49%. This is because reagents are one of the necessary components that are required in laboratories to help process and analyze the DNA. These include bisulfite solution for bisulfite sequencing, magnesium chloride for PCR, etc. In recent years, kits have gained popularity that consist of all the necessary tools and materials along with the reagent, that are required for testing. Additionally, as various organizations are highly focused on research and development, there would be a high demand for several types of reagents with desired properties, which shows their demand in the coming years as well. Therefore, kits & reagents are the primary components required in the laboratories to proceed with the epigenetics diagnosis, thus leading the market, and this dominance is expected to continue in the future years as well.

Europe Epigenetics Diagnostic Market (2025-30): Regional Projections

Geographically, the Europe Epigenetics Diagnostic Market expands across:

• The UK
• Germany
• France
• Italy
• Spain
• The Netherlands
• Scandinavia
• Rest of Europe

Regionally, Germany is the major user of epigenetics diagnostics services with a market share of around 36%. This is because of the highest number of chronic diseases in this region, a well-developed healthcare sector, and high disposable incomes. As per the Global Cancer Observatory, the number of new cases of cancer in Germany was around 6.05,805 in 2022. As epigenetic diagnostics are mainly used in detecting cancer, these high numbers of cancer cases push people to invest in these services, which is fueled by their high incomes. Moreover, Germany consists of more than 600 pharmaceutical companies, which are also prominent users of such services, thus further increasing their demand. Therefore, the presence of a wide consumer base of epigenetics diagnostics is the main reason behind this region’s dominance, which is expected to remain in the forecast years as well.

Europe Epigenetics Diagnostic Industry Recent Development:

• 2025: Roche Sequencing Solutions introduced sequencing by expansion (SBX), a leap forward in next-generation sequencing (NGS). This innovation is fast and plays a vital role in decoding complex diseases such as cancer, immune diseases, and neurodegenerative conditions.

Gain a Competitive Edge with Our Europe Epigenetics Diagnostic Market Report

1. Europe Epigenetics Diagnostic Market Report by MarkNtel Advisors provides a detailed & thorough analysis of market size & market share, growth rate, competitive landscape, and key players. This comprehensive analysis helps businesses gain a holistic understanding of market dynamics & make informed decisions.
2. This report also highlights current market trends & future projections, allowing businesses to identify emerging opportunities & potential challenges. By understanding market forecasts, companies can align their strategies & stay ahead of the competition.
3. Europe Epigenetics Diagnostic Market Report aids in assessing & mitigating risks associated with entering or operating in the market. By understanding market dynamics, regulatory frameworks, and potential challenges, businesses can develop strategies to minimize risks & optimize their operations.

*Reports Delivery Format - Market research studies from MarkNtel Advisors are offered in PDF, Excel and PowerPoint formats. Within 24 hours of the payment being successfully received, the report will be sent to your email address.